# CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

> **NCT00270907** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** CT-2103
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00270907
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2013-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270907, "CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00270907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*